Centrosomal aberrations in primary invasive breast cancer are associated with nodal status and hormone receptor expression
Andreas Schneeweiß(German Cancer Research Center), Alwin Krämer(Heidelberg University)
Cited by 61
Related Papers
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
|Journal of Clinical Oncology|2010|887
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Phase III Study of Gemcitabine Plus Docetaxel Compared With Capecitabine Plus Docetaxel for Anthracycline-Pretreated Patients With Metastatic Breast Cancer
|Journal of Clinical Oncology|2009|119
Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130
|Annals of Oncology|2019|115
Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST)
|Annals of Oncology|2023|103